financetom
Business
financetom
/
Business
/
ArcBest Warns Freight Business To Stay Challenging Through 2025
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ArcBest Warns Freight Business To Stay Challenging Through 2025
Nov 5, 2025 9:09 AM

ArcBest Corp. ( ARCB ) shares fell Wednesday following the company’s third-quarter 2025 results, which beat analyst expectations on both adjusted earnings and revenue.

Adjusted EPS was $1.46, topping the $1.37 estimate, while sales reached $1.048 billion, exceeding the $1.038 billion forecast.

GAAP EPS was $1.72, compared with $4.23 a year earlier, which included a one-time $69.1 million after-tax benefit from the MoLo acquisition.

Also Read: ArcBest Stock’s Arc Probably Wasn’t Its Best

Net income from continuing operations was $39.3 million, compared with $100.3 million in the same period last year. On a non-GAAP basis, net income was $33.4 million, versus $38.8 million in the prior year.

In the Asset-Based segment, revenue rose to $726.5 million from $709.7 million, with tonnage per day up 2.3% and shipments per day up 4.3%.

Billed revenue per hundredweight decreased 1.1%. Operating income was $70.2 million, with an operating ratio of 90.3%, including $15.9 million in asset sale gains.

Excluding those gains, non-GAAP operating income was $54.4 million, with an operating ratio of 92.5%. Customer contract renewals and deferred pricing resulted in a 4.5% increase, while the cost per shipment improved by 1% year over year.

In the Asset-Light segment, revenue totaled $356 million, down from $385.3 million. Revenue decline was primarily due to lower revenue per shipment in a soft-rate environment and a higher mix of managed transportation business, which typically involves smaller, lower-revenue shipments.

The segment reported an operating loss of $1.6 million; on a non-GAAP basis, operating income was $1.6 million, and adjusted EBITDA reached $3.1 million. Shipments per day increased by 2.5%, and productivity reached a record, measured by shipments per person per day.

Balance Sheet and Capital Returns

Year-to-date, ArcBest ( ARCB ) has returned more than $66 million to shareholders through repurchases and dividends. The company ended the quarter with $120.6 million in cash and total long-term debt of $135.5 million, plus $78.6 million in the current portion.

Operating cash flow for the first nine months totaled $184.3 million.

Management stated that asset-based shipment and tonnage growth continued despite a soft freight environment, while Asset-Light achieved record productivity amid ongoing industry-wide pricing pressures.

Market Headwinds Pressure Both Segments

In October 2025, Asset-Based performance softened, with slower shipment growth and declines in both weight per shipment and daily tonnage compared with the prior year. Revenue per hundredweight was essentially flat.

Sequentially, shipments per day and daily tonnage declined modestly, while revenue per hundredweight slipped about 1 percent. Management now expects the non-GAAP operating ratio to worsen by roughly 400 basis points from the third quarter to the fourth quarter, a steeper pullback than the typical 100–200 basis-point seasonal decline, reflecting continued freight-market weakness.

In the Asset-Light segment, daily revenue fell year over year as lower revenue per shipment and a higher mix of smaller Managed loads weighed on results, though shipment volumes increased on steady demand for Managed solutions. Month over month, daily revenue dipped about 3% as shipments per day fell 9%, while revenue per shipment rose 6 percent—consistent with normal seasonal patterns.

Management anticipates a non-GAAP operating loss of $1 million to $3 million in the fourth quarter of 2025, excluding any contingent-consideration fair-value changes (assumed zero) and about $3 million of purchase-accounting amortization.

Price Action: ARCB shares were trading lower by 3.15% to $69.14 at last check Wednesday.

Read Next:

SoftBank Shares Plummet Over 10% In Japan Amid Valuation Jitters — Arm Holdings, Samsung, SK Hynix Also Feel The Heat

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved